The Court ruled that New Zealand is bound by the TRIPS Agreement that obliges it to provide patent protection for all inventions, without discrimination. In the view of the Court, claims on the use of a known compound for the manufacture of pharmaceutical compositions in which the compound exhibits previously unknown therapeutic activity are inventions.